Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis

Tiao Lin(Second Affiliated Hospital of Zhejiang University), Shi-Gui Yan(Second Affiliated Hospital of Zhejiang University), Zhimin Ying(Second Affiliated Hospital of Zhejiang University), C. Wang(Second Affiliated Hospital of Zhejiang University), Xun-Zi Cai(Second Affiliated Hospital of Zhejiang University), Xiaoying Zhao(Handan College), Fuzhen Yuan(Second Affiliated Hospital of Zhejiang University), Chao Guo(Jiangnan University), Mengxia Shi(Second Affiliated Hospital of Zhejiang University)
International Journal of Clinical Practice
February 7, 2012
10.1111/j.1742-1241.2011.02806.x
Cited by 61

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2013|247
Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis
|BMC Cancer|2014|146
Systemic Lupus Erythematous and Malignancy Risk: A Meta-Analysis
|PLoS ONE|2015|115